Dai­ichi Sankyo sweeps out Pieris drug, 5 oth­ers in a Q1 pipeline cleanup

Just a few days af­ter lin­ing up $57.5 mil­lion in near-term cash from a high-pro­file col­lab­o­ra­tion deal with As­traZeneca on its An­ti­calin plat­form, one of Pieris’ oth­er part­ners un­cer­e­mo­ni­ous­ly swept out one of their clin­i­cal-stage ther­a­pies in a Q1 pipeline cleanup.

DS-9001 was dropped by Dai­ichi Sankyo af­ter in­ves­ti­ga­tors re­viewed the da­ta they had on the Phase I ther­a­py tar­get­ing PC­SK9. Pieris $PIRS has been work­ing for years on en­gi­neer­ing pro­teins that are lighter and more ver­sa­tile than an­ti­bod­ies, so that they can work where an­ti­bod­ies find their en­try barred.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.